Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease

Collagenase Clostridium Histolytic is a Common Treatment of MCP and PIP Joint Contractures in Dupuytren Disease. A 1 to 4 Year Followup Study of 198 Joints

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03331926

Enrollment

199

Registered

2017-11-06

Start date

2017-01-01

Completion date

2019-12-31

Last updated

2020-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dupuytren Contracture

Brief summary

To evaluate the effect of collagenase clostridium histolyticum treatment at the Department of Orthopaedic surgery at Horsens Regional Hospital after minimum one-year follow-up (FU).

Interventions

DRUGXiapex

Follow-up of effect of treatment

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* dupuytrens disease * xiapex treatment

Exclusion criteria

\- demens/other psychiatric diseases

Design outcomes

Primary

Measure	Time frame
Change in extension deficit from baseline to FU in MCP and PIP joints after treatment	Minimum one year after treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026